Try as they might with add-ons like pneumatic tires and vacuum insulation, the competition hasn't been able to knock Yeti off its pedestal as the go-to for rugged adventure coolers. Dometic might ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer ...

TOKYO & BASKING RIDGE, N.J. - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) announced positive results from the phase 3 DESTINY-Breast09 trial, indicating that their drug ENHERTU®, ...

Enhertu’s revenue soared by 45% year-over-year to ¥651 billion, significantly contributing to the company’s overall revenue growth. Sales of the anticoagulant Edoxaban also increased by 20% ...

WILMINGTON, Del., June 02, 2025--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

The cancer drug Enhertu stalled the growth of tumors by well over a year in a group of women with a type of metastatic but previously untreated breast cancer, a new study found.

TOKYO & BASKING RIDGE, N.J., May 31, 2025--ENHERTU Reduced Risk of Death by 30% as 2L Therapy in Patients w/HER2+ Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Phase 3 Trial ...

AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announce that Enhertu hit the main goal in a Phase 3 trial for early-stage HER2-positive breast cancer. Read more here.

Turtle Beach Recon 70 review This ultra-cheap headset is an admirable attempt at a solid budget set of cans, but spending just a little more will make a big difference in terms of all-around quality.

AstraZeneca's Enhertu shows significant success in late-stage trials as a first-line treatment for HER2-positive metastatic breast cancer. Read more here.

Enhertu is currently approved as a second-line treatment for HER2-positive metastatic breast cancer. The new results for the AstraZeneca and Daiichi Sankyo drug in the first-line setting are ...